Institut Pasteur

Other

Fran&ccedil;ois Clavel

Luc Montagnier

Pierre Sonigo

Marc Alizon

Denise Guetard

Mireille Guyader

Solange Chamaret

Fran&ccedil;oise Brun-Vezinet

Pierre Charneau

Christine Rouzioux

Christine Katlama

Marianne Rey

Simon Wain-Hobson

Jean-Claude Chermann

Stewart T Cole

Bernard Krust

Sylvie Paulous

Olivier Danos

Jacques Cohen

Andrew Borman

Caroline Quillent

Jacqueline Donjon De Saint-Martin

V&eacute;ronique Zennou

Esther Race

V&eacute;ronique Obry

Elisabeth Dam

Luc Montangnier

Fran&ccedil;oise Barre-Sinoussi

Method for preparing a viral extract containing HIV-II RNA

The invention provides an in vitro single cycle, recombinant virus assay (RVA) for determining inhibition of HIV replication by a protease inhibitor. The assay comprises transfecting a human epithelial cell line with amplified HIV protease sequences of an HIV virus; an HIV envelope defective molecular clone having a complete deletion of its protease coding sequence as well as two separate deletions in its env gene and a deletion of part of its gag gene; and a plasmid containing HIV envelope coding sequence under the control of a promoter for phenotypic complementation of the envelope defective molecular clone. The transfected cells are cultured in the presence of a protease inhibitor to produce a testable stock of infectious particles that can be used to infect indicator cells containing an indicator gene without amplification of the infectious particles prior to infecting the indicator cells. Accumulation of indicator gene product is a measure of inhibition of HIV replication by the protease inhibitor.

Rapid single-cycle assay for human immunodeficiency virus type 1 drug resistance

The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone &lgr;J19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and various hydrophilic peptides obtained therefrom. These peptides correspond to amino acids 551-577, 594-603, 621-630, 657-679, and 719-758 of the LAV envelope glycoprotein. These peptides should provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.

Nucleic acids and peptides of human immunodeficiency virus type (HIV-1)

The present invention is directed toward a novel human retrovirus isolated from West African AIDS patients. This virus was originally designated lymphadenopathy associated virus (LAV) type II and subsequently renamed the human immunodeficiency virus type 2, or HIV-2. This virus is genotypically and phenotypically distinct from both human immunodeficiency virus type 1 (HIV-1) and the simian immunodeficiency virus (SIV). A recombinant &lgr; phage library was prepared by subjecting HIV-2-infected CEM genomic DNA to digestion with Sau3AI. The library was screened with an HIV-2-specific cDNA probe and molecular clones of the virus were obtained. Restriction maps and the nucleotide sequences of these clones were ascertained. These nucleic acids should prove useful, inter alia, as probes for the detection of HIV-2 in biological samples and for the expression of HIV-2 gene products.

Nucleic acids of a human immunodeficiency virus type 2 (HIV-2)

An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.

Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens

The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.

In vitro diagnostic methods and kits for the detection of HIV-2-specific antibodies

Growing community of inventors

Paris, France

François Clavel

Growing community of inventors

Paris, France

Fran&ccedil;ois Clavel

François Clavel